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ABSTRACT 1 
The role of the polyomavirus BK (BKV) large tumor antigen (L-Tag) as target of immune 2 
response in patients with prostate cancer (PCa) has not been investigated so far. In this study we 3 
have comparatively analyzed humoral and cellular L-Tag specific responsiveness in age matched 4 
patients bearing PCa or benign prostatic hyperplasia (BPH), expressing or not expressing BKV 5 
L-Tag specific sequences in their tissue specimens, and in non-age-matched healthy individuals. 6 
Furthermore, results from patients with PCa were correlated to 5-year follow-up clinical data 7 
focusing on evidence of biochemical recurrence (BR) following surgery (PSA≥0.2ng/ml).  8 
 In peripheral blood mononuclear cells (PBMC) from patients with PCa with evidence of BR 9 
and BKV L-Tag positive tumors, stimulation with peptides derived from BKV L-Tag, but not 10 
those derived from Epstein Barr virus, influenza virus or Cytomegalovirus, induced a peculiar 11 
cytokine gene expression profile, characterized by high expression of IL-10 and TGFβ-1 and a 12 
low expression of IFN-γ genes. This pattern was confirmed by protein secretion data and 13 
correlated with high levels of anti BKV L-Tag IgG. Furthermore, in PBMC from these PCa 14 
bearing patients, L-Tag derived peptides significantly expanded an IL-10-secreting 15 
CD4+CD25+(high)CD127-(dim)FoxP3+ T cell population with an effector memory phenotype 16 
(CD103+) capable of inhibiting proliferation of autologous anti-CD3/CD28 triggered CD4+CD25- 17 
T cells. Collectively, our findings indicate that potentially tolerogenic features of L-Tag specific 18 
immune response are significantly associated with tumor progression in patients with BKV+ 19 
PCa.  20 
KEY WORDS 21 
Human Polyomavirus BK Large Tumor Antigen, Prostate Cancer, Regulatory T cells, Viral 22 
Immunology.   23 
24 
 4 
INTRODUCTION  1 
Prostate cancer (PCa) represents the first leading cause of cancer morbidity and the third 2 
of cancer death in men in developed countries with a worldwide incidence rate of 14% of total 3 
newly diagnosed malignancies and a worldwide total cancer mortality rate of 6% (29). A 4 
contemporary model of PCa induction and progression should include the analysis of the 5 
contribution of inflammation to the development of preneoplastic or neoplastic lesions (24). 6 
Indeed, proliferative inflammatory atrophy (PIA) of the prostate has recently gained importance 7 
as potential precursor of prostatic intraepithelial neoplasia (PIN) and overt PCa (15), (14). This 8 
owes particularly to the prevalence of PIA in the peripheral zone of the organ, where histological 9 
transition between PIA and PIN usually occurs (42).  10 
The low rate of mutations detected in tumor suppressor genes pRB1 and p53 in primary PCa 11 
cells (16) has suggested a possible role of inflammatory agents ubiquitous in the urinary tract 12 
with unique oncogenic functions, that is of sequestering wild-type products of tumor suppressor 13 
genes. Polyomaviruses’ main regulatory proteins large tumor antigens (L-Tag) interfere with wt-14 
p53 binding to cellular DNA during virus infection (4), thereby impairing p53 control on cell 15 
growth activity and possibly leading to oncogenic transformation in non-permissive cells (6). As 16 
such, the human urotheliotrophic polyomavirus BK (BKV) has been suggested to prominently 17 
associate with the development of cancer (26, 27), and, in particular, of urinary tract 18 
malignancies (3, 12, 54).  19 
There is a continuing debate on BKV expression in overt cancers (1, 5). However, the 20 
possibility of “hit and run” carcinogenic mechanisms induced by BKV cannot be excluded (13). 21 
Genetically rearranged BKV variants (45), (22), presumably difficult to detect by commonly used 22 
assays, might exist in the urinary tract and be responsible for neoplastic transformation in prostate 23 
 5 
cells (i.e. URO-1) (37). Therefore, BKV has been indicated as potential co-factor in the earliest 1 
stages of PCa (13).  2 
Detection and expression of BKV L-Tag sequences in preneoplastic prostate tissues (12) have 3 
prompted us to investigate the role of this viral antigen as target of immune response. Thus, in 4 
this study we have addressed humoral and cellular responsiveness to BKV L-Tag in patients with 5 
benign prostatic hyperplasia (BPH) or newly diagnosed PCa and we have correlated viral and 6 
immunological features with PCa status.  7 
8 
 6 
PATIENTS & METHODS 1 
Patients and clinical follow-up  2 
One hundred ten consecutive patients diagnosed for either prostate cancer (PCa, n=60; 3 
PSA>4ng/ml and suspicious digital rectal examination (DRE) and/or positive for early diagnosed 4 
high grade prostate intraepithelial neoplasm (HGPIN) at biopsy) or benign prostate hyperplasia 5 
(BPH n=50; urinary obstructive symptoms and acute urinary retention according to the 6 
International Prostate Symptom Score, IPSS) were enrolled in the study at the Department of 7 
Urology of the University Hospital of Basel, Switzerland, and at the Division of Urology of the 8 
University Hospital of Zurich, Switzerland, upon informed consent, following approval by 9 
Cantonal Ethical Committees of Basel and Zurich. Five-year follow-up after surgery was 10 
completed for 48/60 PCa patients (80%). Timing of biochemical recurrence (BR+), with early 11 
censoring if only 1 or 2 values were available, was established at the first ≥0.2ng/ml PSA 12 
detection. BR- patients were those showing clearly negative PSA values (<0.04ng/ml) during 13 
complete follow-up. Data were collected according to the American Society for Therapeutic 14 
Radiation and Oncology (ASTRO) criteria (23), considering both ACTUARIAL and ASTRO-15 
time analytical methods, since ASTRO-censoring allowed to define biochemical failure by 3 16 
consecutive increases in PSA values in 3/48 PCa only. 17 
 18 
Virus detection in tissue specimens  19 
Specimens from tissues excised during surgical procedures were formalin-fixed and 20 
paraffin-embedded. DNA was extracted from 3 sections (thickness, 5 µm) randomly picked 21 
within the tumor area (PCa) or within the atrophic-hyperplastic gland (BPH) using the QIAamp 22 
DNA Mini Kit (Qiagen, Basel, Switzerland), according to the manufacturer’s instructions. 23 
 7 
Molecular detection of polyomavirus BK was performed by qRT-PCR using a TaqMan assay 1 
targeting L-Tag. The assay, named T3a, consists of a primer/probe set which has been designed 2 
to reliably measure BKV L-Tag subtypes Ia, Ic, III, IV and VI (25). PCR amplification was set up 3 
according to standard real-time PCR protocols, using a Corbett life science Rotor-gene 3000 4 
instrument (Corbett Life science, Sydney, Australia). Standard curves for the quantification of 5 
BKV L-Tag were generated using serial 10-fold dilutions of plasmid pBKV35-1 DNA (LGC 6 
Standards Sarl, Molsheim, France). To correct for the variable amounts of DNA in individual 7 
tissue specimens, amplification of control gene aspartoacylase (ACY) was performed in each 8 
sample, as previously described (43). Patients were considered BKV L-Tag negative upon 9 
consecutive negative testing on all three randomly picked punches.  10 
 11 
Enzyme Immunoassay (EIA) for patient and donor serology  12 
BKV specific antibody detection was performed by enzyme immunoassay (EIA) with 13 
GST-BKV fusion protein. Optical densities (OD492) were measured using an automated plate 14 
reader (Tecan Group Ltd., Männedorf, Switzerland) at 492 nm. Affinity-purified GST was run as 15 
a negative control and corresponding OD values were subtracted from GST-BKV L-Tag domain 16 
1 (LTD1) and GST-BKV VP1 specific signals. The cut-off was defined as two standard 17 
deviations above mean values of negative controls. Therefore, all OD values <0.04 were 18 
considered negative (7, 33).  19 
 20 
Peptides and peptide pools   21 
BKV Large T antigen (L-Tag) peptide-pool was provided by JPT Peptide Technology 22 
(Berlin, Germany). This PepMix contains a total of 170 15mer peptides spanning the entire 23 
 8 
antigen (691 amino acids, Swiss-Prot P14999) and tiled at 11 amino acid pace. Similarly, the 1 
negative control PepMix HIVgag peptide-pool (123 peptides including B gag motif) was also 2 
provided by JPT. As positive control, the PepMix CEF (Cytomegalovirus, Epstein Barr virus and 3 
Influenza virus) pool of 23 8-11mer peptides recognized by CD8 positive T cells and presented 4 
by 11 class I HLA-A and HLA-B alleles (11) was used (JPT, Berlin Germany). For in vitro 5 
expansion and proliferation assays, both HIV peptide-pool (see above) and the Human 6 
Cytomegalovirus promiscuous epitope pp65340-355 (41) (Princeton Biomolecules, Langhorne, PA, 7 
USA) were used as controls.  8 
 9 
 “Ex vivo” induction and detection of cytokine gene expression by qRT-PCR   10 
Peripheral blood mononuclear cells (PBMC) isolated from venous blood by Ficoll-11 
Hypaque density gradient centrifugation were resuspended in RPMI medium supplemented with 12 
100 µg/ml Kanamycin, 10 mM Hepes, 1mM sodium pyruvate, 1 mM Glutamax and nonessential 13 
amino acids (all from GIBCO Paisley, Scotland) (complete medium) and 5% human serum 14 
(Blutspendezentrum UniversitätsSpital Basel, Switzerland), at a final concentration of 1×106 15 
cells/ml, plated in 96 U-bottom well plates (200 µl/well) and incubated for overnight resting. 16 
Cells were then stimulated with either test (L-Tag) or control (CEF, HIV) peptide-pool (1 µg/ml) 17 
or PHA (1 µg/ml) and harvested after 3 hours for RNA extraction (RNeasy® Mini Kit Protocol, 18 
Qiagen, Basel, Switzerland) and cDNA synthesis (Invitrogen, Carlsbad, CA, USA). Quantitative 19 
gene amplification (qRT-PCR) was performed, as previously described (40), by an ABI prism™ 20 
7500 FAST sequence detection system using TaqMan® Universal PCR Master Mix Reagents Kit 21 
and “on demand” sets of primers and probes for cytokine gene expression (IFN-γ, IL-10, TGF-22 
 9 
β1) (Applied Biosystems, Rotkreuz, Switzerland). β-actin was used as endogenous reference 1 
gene and normalized data were analyzed by the 2-∆∆Ct method (34).  2 
 3 
Cell cultures 4 
Monocytes (CD14+) sorted from PBMC by magnetic beads (Miltenyi Biotech) were 5 
cultured from 5 to 7 days in RPMI complete medium supplemented with 10% FCS (GIBCO 6 
Paisley, Scotland), 0.004% β-mercaptoethanol, rhIL-4 (1000 U/ml) and rhGM-CSF (50 ng/ml) to 7 
generate immature DCs (iDCs). To induce maturation, iDCs were overnight exposed to 1 μg/ml 8 
LPS (Abortus Aequi, Sigma-Aldrich, St. Louis, MO, USA). CD4+ T cells positively sorted from 9 
PBMC by magnetic beads were cultured in complete medium with 5% human serum in 24 flat-10 
bottom well plates at a 1x106 cells/ml concentration in the presence of autologous irradiated 11 
mature DC (mDCs), previously pulsed for 2 hours with peptide pools (10 µg/ml), either for 12 
priming (day 0) or re-stimulation (day 7). Recombinant human IL-2 (rhIL-2; Hoffmann-LaRoche, 13 
Basel, Switzerland) was added to cultures at 1ng/ml, 1ng/ml and 5ng/ml, on days 3, 7 and 10, 14 
respectively.  15 
Regulatory T cell cultures were established by ex vivo magnetic sorting of 16 
CD4+C25+CD127-/dim subset, as previously described (48). Cells were subsequently stimulated 17 
with L-Tag peptide-pool (5µg/ml) or control peptides, including HCMVpp65340-355 and HIV 18 
peptide-pool, in the presence of 10 µg/ml anti-CD28 (BD Bioscience, Allschwil, Switzerland) 19 
and 5 ng/ml of rIL-2. Cultures were similarly restimulated on day 7. IL-10-secreting Treg were 20 
sorted on day 14 by cytokine secretion assay (Miltenyi Biotec, Germany). For suppression 21 
assays, CD4+CD25+(high) CD127-(dim), IL-10-secreting T cells were cultured in the upper chamber 22 
of 24-transwell plates (BD Bioscience, Allschwil, Switzerland) with a double amount 23 
 10 
(ratio=0.5:1) of autologous CD4+CD25- T cells, stimulated with 1mg/ml of anti CD3/CD28 (BD 1 
Bioscience, Allschwil, Switzerland) seeded in the lower chamber, and cultured for 8 days. 2 
CD4+CD25- T cells proliferation was measured using Cell Proliferation Reagent WST-1 (Roche 3 
Applied Science, Rotkreutz, Switzerland) according to manufacturer’s instructions and 4 
absorbance was read at 450nm with an ELISA plate reader.   5 
 6 
Regulatory T cell quantification by flow cytometry  7 
CD4+ T cells stimulated by peptide-pools, as described above, were stained with anti-CD4 8 
FITC and anti-CD25 APC antibodies (BD Biosciences, Allschwil, Switzerland). Anti FoxP3 PE 9 
antibodies and FoxP3 Fix/Perm buffer were used for intracellular staining according to 10 
manufacturer's protocol (eBioscience, Vienna, Austria). Separation into CD25 bright (CD25high) 11 
and CD25 dim (CD25low) cells was carried out using a fluorescence cut-off defined in healthy 12 
donors (HD). Anti-CD103 PerCP (eBioscience, Vienna, Austria) and anti-IL-10 APC 13 
intracellular staining (BD Bioscience, Allschwil, Switzerland) were additionally carried out for 14 
the identification of IL-10-secreting activated Treg. Data were acquired on a FACSCalibur flow-15 
cytometer equipped with Cellquest software (Becton Dickinson, San Jose`, CA, USA).  16 
 17 
Cytokine measurement 18 
The FlowCytomix Simple kit (eBioscience, Vienna, Austria) was used to measure IFN-γ, 19 
IL-10 and TGF-β1 protein release in culture supernatants of peptide-stimulated T cells. Samples 20 
were run on a FACSCalibur flow-cytometer equipped with Cellquest software (Becton 21 
Dickinson, San Jose`, CA, USA), analyzed with BMS FlowCytomix software (eBioscience, 22 
Vienna, Austria), and referred to a standard curve for quantification.  23 
 11 
Statistical analysis 1 
Statistical analysis was performed with Graph Pad Prism (version 5.1) and SAS/STAT 2 
(version 9.1). Data were reported as mean ± standard deviations (SD) or mean ± standard errors 3 
(SE), median and ranges where appropriate. Distributions of categorical markers were analyzed 4 
by both χ2 and Fisher’s exact tests. Groups following normal distribution (Shapiro-Wilk test) 5 
were compared with t-tests (either Pooled or Cochran method) and F-test was used to calculate 6 
variance among groups of samples. If non-normal distribution was indicated, nonparametric tests 7 
such as Mann-Whitney U tests and Spearman’s ρ correlation analyses were used. P values <0.05 8 
(CI 95%) were considered statistically significant. 9 
10 
 12 
RESULTS 1 
Clinical profiles of patients  2 
The average age of patients enrolled in the study (n=110) was 64±7.7 years (range 49-90) for 3 
PCa (n=60) and 67±7.4 years (range 48-81) for age-matched BPH (n=50), respectively.  4 
Out of 60 PCa patients, 1 was diagnosed with clinical stage pT1b, 10 with pT2a, 2 with pT2b, 5 
the majority (n=30; 51%) with clinical stage pT2c, 4 with pT3a and 3 with pT3b. Ten (17%) 6 
patients had tumors whose stage at diagnosis could not be assessed. Average serum prostate 7 
specific antigen (PSA) value was 17.4±36.2 ng/ml (median: 6.7 ng/ml, range: 1.6-206 ng/ml) in 8 
PCa patients before surgery (n=50, 83%) and 5.6±5.7 ng/ml (median: 3.9 ng/ml, range: 0.4-26 9 
ng/ml) in BPH patients (n=36, 72%). Gleason Score (GS) of tumor specimens (n=55, 92%) 10 
ranged from 5 to 9 according to immunohistochemical analysis (Table 1). 11 
 12 
 L-Tag DNA detection in tissue specimens and BKV specific humoral response 13 
Presence of polyomavirus BK was analyzed by BKV L-Tag DNA detection in surgically 14 
excised PCa (n=43/60, 72%) and BPH (n=38/50, 76%) specimens. Positive samples (hereafter 15 
referred to as BKV+) were identified among both PCa (mean=451.4 copies/105cells; n=18/43, 16 
42%) and BPH (mean=391.5 copies/105cells; n=12/38, 32%) with no significant quantitative 17 
differences among groups of patients (p=0.72) (Figure 1a). No significant association (χ2) with 18 
cancer (p=0.18) or Gleason Score (GS+ ≥7; p=0.82) was observed. However, high PSA levels 19 
(PSA ≥4ng/ml) were more frequently detectable in sera from patients with BKV+ PCa (p<0.05).  20 
Humoral response against BKV VP1- and L-Tag was analyzed in sera from patients with PCa 21 
and BPH. Upon sample stratification based on BKV L-Tag DNA tissue testing, we noted that 22 
levels of L-Tag specific IgG (OD) were significantly higher in patients bearing BKV+ than BKV- 23 
 13 
PCa (p=0.01), while they were similarly low in patients with BKV+ or BKV- BPH. In contrast, 1 
anti VP1 IgG levels were similar in patients with PCa or BPH, irrespective of their BKV 2 
molecular status (Figure 1b). Overall, detectable evidence of humoral responsiveness to L-Tag 3 
(OD≥0.04) was observed in 17/18 (94%) patients with BKV+ PCa and in 7/12 (58%) patients 4 
with BKV+ BPH with a significant association (χ2) between BKV+ lesions and L-Tag IgG only 5 
in patients with PCa (p=0.005) (Table 1). 6 
 7 
Cytokine gene expression pattern in PBMC from patients with PCa or BPH upon ex vivo 8 
BKV L-Tag peptide-pool stimulation 9 
Humoral response data, showing a high level of L-Tag IgG response in patients bearing 10 
BKV+ PCa, prompted us to explore cellular immune responsiveness to this antigen. Freshly 11 
isolated PBMC from 60 patients with PCa and 50 age-matched patients with BPH were 3-hour ex 12 
vivo stimulated with an L-Tag peptide-pool and IFN-γ and IL-10 cytokine gene expression were 13 
used as readout. A HIV peptide-pool with B gag motif was used as negative control to provide a 14 
baseline allowing the calculation of cytokine gene expression fold changes.  15 
In L-Tag IgG seronegative patients (PCa n=14, BPH n=12, Table 1), regardless of underlying 16 
disease, L-Tag peptide-pool stimulated cytokine gene expression was usually low (Figure 2a). 17 
However, in L-Tag IgG+ patients with PCa (n=46), L-Tag peptide-pool induced a significantly 18 
higher IL-10 gene expression, (p=0.03), but rather a decreased IFN-γ gene expression (p=0.04) as 19 
compared to seronegative patients. In contrast, in L-Tag IgG+ patients with BPH (n=38) L-Tag 20 
peptide-pool did not induce significantly higher IFN-γ (p=0.8) and IL-10 (p=0.9) gene 21 
expression, as compared to seronegative patients. Accordingly, these tests also showed that L-22 
Tag peptide-pool induced a higher IL-10 than IFN-γ gene expression in L-Tag IgG+ patients with 23 
 14 
PCa (n=46; p=0.0001) and, to a lesser, non-significant, extent, in L-Tag IgG+ patients with BPH 1 
(n=38; p=0.06) (Figure 2a).  2 
To investigate the relationship eventually occurring between BKV L-Tag specific humoral 3 
response and L-Tag-specific gene expression pattern, L-Tag specific IgG activity was plotted 4 
against IL-10/IFN-γ gene expression ratio. A significant direct correlation was indeed observed in 5 
patients with PCa (Spearman: ρ=0.4, p=0.009), but not in patients with BPH (ρ=-0.2, p=0.3) 6 
(Figure 2b). 7 
These results urged us to comparatively investigate cytokine gene expression induced by L-8 
Tag peptide-pool, CEF peptide-pool or PHA in L-Tag seropositive patients with PCa or BPH and 9 
in seropositive gender but not age-matched healthy donors (HD). Contrary to PBMC from IgG+ 10 
patients with PCa and BPH (see above), L-Tag peptide-pool stimulation of PBMC from L-Tag 11 
IgG+ HD induced a IFN-γ gene expression significantly higher than IL-10 gene expression (n=8; 12 
p=0.003). Most importantly, CEF peptide-pool and PHA induced a similar, significantly higher 13 
IFN-γ than IL-10 gene expression in PBMC from patients with PCa or BPH (p<0.0001) or from 14 
HD (p<0.001) (Figure 2c). 15 
Notably, IL-10 gene expression induced by L-Tag peptide-pool was significantly higher 16 
than IL-10 gene expression induced by CEF or PHA in PBMC from L-Tag IgG+ patients with 17 
PCa (p<0.0001 and p=0.0002, respectively) or BPH (p<0.0001 and p=0.001, respectively) 18 
(Figure 2c). In PBMC from HD, IL-10 gene expression was similarly negligible irrespective of 19 
the stimuli used. 20 
Remarkably, IFN-γ gene expression could be induced by CEF of PHA to comparably high 21 
extents in PBMC from L-Tag IgG+ patients with PCa or BPH or from HD (Figure 2c), thereby 22 
 15 
suggesting a specificity of the cytokine gene expression pattern induced by L-Tag stimulation in 1 
PBMC from L-Tag IgG+ patients. 2 
 3 
BKV L-Tag peptide-pool stimulated cytokine gene expression pattern in PBMC from 4 
patients bearing BKV+ PCa or BPH 5 
We then evaluated in detail L-Tag specific cellular immune response in patients bearing 6 
BKV+ or BKV- PCa or BPH. The analysis of these data confirmed that a highly significant 7 
increase in IL-10 gene expression upon L-Tag peptide-pool stimulation was detectable in PBMC 8 
from patients bearing a BKV+ PCa as compared to those from patients bearing BKV- PCa 9 
(p<0.0001). In contrast, IFN-γ gene expression induced by L-Tag peptide-pool was modest, but 10 
detectable in PBMC from patients with BKV- PCa, and significantly higher than that detectable 11 
in similarly stimulated PBMC from patients bearing BKV+ PCa (p=0.02) (Figure 3a). On the 12 
other hand, expression of IFN-γ and IL-10 genes upon L-Tag peptide-pool stimulation was 13 
similar in PBMC from patients bearing BKV+ or BKV- BPH.  14 
An analysis limited to patients with evidence of BKV L-Tag specific IgG also showed a 15 
highly significant (p<0.0001) predominance of IL-10 vs. IFN-γ gene expression in patients 16 
bearing BKV+ prostate lesions. In contrast, IFN-γ and IL-10 gene expression detectable upon L-17 
Tag triggered PBMC stimulation were similar in L-Tag IgG+ patients with BKV+ BPH (Figure 18 
3b). 19 
Indeed, although IL-10 gene expression did not significantly differ between patients with 20 
BKV+ PCa or BKV+ BPH (p>0.05) (Figure 3a and 3b), most interestingly, IL-10/IFN-γ gene 21 
expression ratio was significantly (p=0.04) higher in BKV specific IgG+ patients bearing BKV+ 22 
PCa (n=17) than in BKV specific IgG+ patients with BKV+ BPH (n=6) (Figure 3c). 23 
 16 
 Comparative analysis of L-Tag induced cytokine gene expression in patients bearing BKV+ 1 
PCa with or without evidence of biochemical recurrence (BR).  2 
The results obtained in the first part of our study suggested that BKV specific immune 3 
response is characterized by specific features, particularly in patients bearing BKV+ PCa, as 4 
compared to patients with BPH, let alone healthy donors. These data raised the obvious issue of 5 
the association of this response pattern with PCa clinical course. 6 
Therefore, considering their peculiar clinical condition, we analyzed in detail BKV L-Tag 7 
peptide-induced cytokine gene expression in PBMC from patients bearing BKV+ cancers with 8 
biochemical evidence of recurrence (BR+). BR was observed in 9/48 (19%) patients with PCa 9 
with complete follow-up, after 6 weeks (n=6), 24 weeks (n=1), 48 weeks (n=1) and 96 weeks 10 
(n=1). Two patients were excluded from the study because BKV molecular testing on tissue 11 
lesions was not available (nt) (Table 2). Despite the limited number of BR+ PCa patients, a 12 
significant association between BR status and BKV+ lesions, irrespective of serological status, 13 
was observed. Indeed, in 7/16 patients bearing BKV+ PCa, evidence of BR was detectable within 14 
a 96 weeks follow up, as compared to none of 17 patients with BKV- PCa (Fisher exact test, 15 
p=0.004).  16 
Then, we comparatively analyzed cytokine gene expression upon L-Tag stimulation in 17 
patients with BKV+ PCa stratified based on evidence of BR. In order to evaluate a more 18 
homogeneous test group, we excluded the only BR- patient with BKV+ PCa, seronegative for L-19 
Tag specific IgG (Table 2).  20 
In BKV L-Tag specific IgG+ patients with BKV+ PCa (n=15), a distinctive L-Tag induced 21 
gene signature prominently emerged. Indeed, significantly higher IL-10/IFN-γ (p<0.01) and 22 
TGF-β1/IFN-γ (p=0.02) gene expression ratios were observed in PBMC from patients bearing a 23 
 17 
BKV+ PCa with BR evidence (n=7), as compared with those detectable in PBMC from patients 1 
bearing a BKV+ PCa with no BR evidence (n=8) (Figure 4a). 2 
Importantly, in the former group, the extent of L-Tag specific IgG response was 3 
significantly correlated with both the IL-10/IFN-γ (ρ=0.8, p=0.02) and TGF-β1/IFN-γ (ρ=0.7, 4 
p=0.05) gene expression ratio induced in PBMC by L-Tag peptide stimulation (data not shown).  5 
To verify these findings at the protein level, we cultured CD4+ T cells from patients bearing 6 
BKV+ PCa with (n=7) or without (n=8) evidence of BR in the presence of autologous DC pulsed 7 
with either HIV derived or L-Tag peptide pools and we analyzed IFN-γ, IL-10 and TGF-β1 8 
release upon specific stimulation.  In keeping with gene expression data (see above), we found 9 
that L-Tag specific stimulation in BR+ patients with BKV+ cancers induced a significantly 10 
(p<0.01) lower IFN-γ production and a significantly (p=0.03) higher TGF-β1 production, as 11 
compared to cells from BR- patients bearing BKV+ PCa (figure 4b). Although IL-10 release did 12 
not significantly differ in the two groups, IL-10/IFN-γ protein ratios were significantly (p<0.01) 13 
higher in BR+ patients bearing BKV+ PCa. 14 
 15 
L-Tag peptide-pool stimulation expands CD4+CD25+(high)FoxP3+ T cells in patients bearing 16 
BKV+ PCa with biochemical recurrence  17 
The peculiar gene expression pattern induced by L-Tag in patients bearing BKV+ PCa, and, 18 
particularly, in BR+ patients, prompted us to investigate CD4+ regulatory (CD25+FoxP3+) T cells 19 
in PBMC from these patients, both ex vivo and following L-Tag peptide-pool-specific 20 
stimulation. In particular, to adequately control our study, we focused on cells from L-Tag 21 
specific IgG+ patients bearing BKV+ PCa with or without BR (n=7 and n= 8, respectively) and 22 
from L-Tag specific IgG+ patients bearing BKV+ BPH (n=7) (Table 2). 23 
 18 
Peripheral blood CD4+ T cells from these patients were stained on their surface with anti 1 
CD25 mAb and intracellularly with anti Foxp3 mAb. No differences were detectable between 2 
patients with PCa, irrespective of BR, and patients with BPH regarding CD4+CD25+FoxP3+ T 3 
cells ex vivo frequency (Figure 5a).  4 
CD4+ T cells from the different groups of patients under investigation were then cultured for 5 
2-weeks in the presence of L-Tag pool, HIV pool or HCMVpp65340-355 promiscuous peptide-6 
pulsed autologous mDCs. CD4+CD25+(high) populations in cultured cells were identified as shown 7 
in figure 5b. Following L-Tag peptide-pool stimulation, cultures from BR+ patients bearing 8 
BKV+ PCa contained significantly higher percentages of CD4+CD25+(high)FoxP3+ cells, as 9 
compared to similarly stimulated cultures from BR- patients bearing BKV+ PCa (p<0.001) or to 10 
cultures from patients bearing BKV+ BPH (p<0.001) (Figure 5c). In contrast, HCMVpp65340-355  11 
promiscuous peptide failed to expand CD4+CD25+(high)FoxP3+ cells to extents significantly higher 12 
than HIV pool peptides in cells from any of the patient population under investigation. 13 
Furthermore, FoxP3+ protein expression upon L-Tag, but not HCMVpp65340-355 or HIV pool 14 
peptide stimulation, was significantly enhanced, as evaluated by mean fluorescence intensity  15 
(MFI) measurement, in cells from BR+ patients bearing BKV+ PCa in comparison to cells from 16 
BR- patients bearing BKV+ PCa (p<0.001) or from patients bearing BKV+ BPH (p=0.001) 17 
(Figure 5d). 18 
 19 
Functional effector memory phenotype (CD103) and regulatory activity of BKV L-Tag in 20 
vitro generated CD4+CD25+(high)+CD127-(dim) T cells 21 
To investigate the potential functional relevance of the phenotypic modifications observed 22 
upon L-Tag stimulation, PBMC from BR+ patients bearing BKV+ PCa (n=3) were cultured in 23 
 19 
the presence of L-Tag peptide-pool, HCMVpp65340-355 promiscuous peptide and HIV peptide-1 
pool, as detailed in “materials and methods”. CD4+CD25+(high) T cells were then sorted as CD127-2 
(dim) and incubated in the presence of the antigens used for initial stimulation. High percentages of 3 
L-Tag and HCMVpp65340-355 stimulated CD4+CD25+(high)CD127-(dim) T cells were able to produce 4 
IL-10, as detectable by intracellular staining (99.1±0.2% and 78.9±3.2%, respectively) (figure 5 
6a). However, L-Tag stimulated CD4+CD25+(high)CD127-(dim) T cells showed a higher expression 6 
of CD103, a Treg effector memory marker (35), as compared to HCMVpp65340-355 or HIV 7 
peptide-pool stimulated cells (Figure 6b). Most importantly, L-Tag expanded 8 
CD4+CD25+(high)CD127-(dim), IL-10-secreting T cells were able to inhibit the proliferation of 9 
autologous anti-CD3/CD28 stimulated CD4+CD25- T cells, in co-culture assays at a 0.5:1 ratio, 10 
to a significantly higher extent than HCMVpp65340-355 expanded CD4+CD25+(high)CD127-(dim) T 11 
cells (p<0.0001) (Figure 6c and 6d).  12 
 13 
  14 
 15 
16 
 20 
Discussion 1 
 BKV infection has repeatedly been suggested to be associated with cancers of the 2 
genitourinary tract. However, possibly due to conflicting results regarding detection of specific 3 
sequences and proteins in human cancers, its oncogenic role is controversial (1).  4 
In a recent past, we have analyzed in detail cellular immune responses to BKV L-Tag 5 
derived antigenic epitopes (39). Prompted by these studies we have now addressed key features 6 
of BKV L-Tag specific immune responsiveness in patients with PCa, and their association with 7 
clinical course.  8 
Our data unravel that in patients with PCa, and, in particular, in those showing 9 
biochemical evidence of tumor recurrence (BR+), immune responsiveness to BKV L-Tag is 10 
differentially characterized by a number of conspicuous features, as compared with patients with 11 
no evidence of BR, or patients with BPH.    12 
 Indeed, in patients with BR+ PCa, a high titer of L-Tag specific IgG is significantly 13 
associated with a high IL-10/IFN-γ gene expression ratio as observed following ex vivo PBMC 14 
stimulation with L-Tag peptides. Furthermore, in these patients, L-Tag peptide stimulation of 15 
PBMC in vitro results in a significantly higher expansion of a CD4+CD25+(high)FoxP3+ population 16 
as compared with patients bearing BKV+ PCa without BR evidence or with patients with BKV+ 17 
BPH. Notably, our data indicate that BKV L-Tag gene expression is detectable with similar 18 
frequency and at similar copy numbers in PCa and BPH tissues. Thus, we did not detect a 19 
preferential BKV gene expression in PCa (5), but rather a different pattern of L-Tag specific 20 
immune responses. 21 
At difference with capsid proteins, polyomavirus L-Tag is not present in viral particles, but is 22 
only produced in infected cells and localizes in their nuclei. Therefore, while humoral response to 23 
 21 
capsid proteins is widely detectable following infection, induction of L-Tag specific humoral 1 
responses is less likely to take place, unless cell death repeatedly occurs, which has been suggested 2 
to be the case in cancer tissues (38). Alternatively, we might hypothesize that only BKV abortive 3 
infections, e.g. those possibly leading to cancer transformation of infected cells, would permit L-4 
Tag exposure to the immune system, thus favoring the induction of an antibody response (38). 5 
Indeed, our data show a significant association between L-Tag specific IgG levels and L-Tag 6 
molecular detection in patients with PCa, but not in those with BPH. In contrast, VP1 IgG levels 7 
were similar in patients with PCa and BPH, irrespective of BKV detection in prostate lesions, 8 
partially reflecting humoral responses observed against Merkel cell polyomavirus (MCV) VP1 in 9 
Merkel Cell Carcinoma (MCC), a cancer associated to MCV infection (50).  10 
Cellular immune responsiveness to BKV L-Tag is also characterized by a number of peculiar 11 
features. In particular, in PBMC from patients with PCa, L-Tag peptide specific response is 12 
characterized by an IL-10 gene expression significantly higher than that of IFN-γ gene. In PBMC 13 
from patients with BPH a similar trend is detectable, whereas in cells from HD, IFN-γ gene 14 
expression is significantly higher than that of IL-10 gene. This gene expression pattern is unique 15 
to BKV L-Tag stimulated cells, because in PBMC from patients with PCa, BPH or from HD, 16 
other viral peptides (CEF pool) or PHA similarly induce an IFN-γ gene expression significantly 17 
higher than that of IL-10 gene. Therefore, the skewed responsiveness to BKV L-Tag cannot be 18 
merely attributed to a physiological decline of immune fitness, as frequently occurring in elderly 19 
individuals.  20 
Taken together, these data suggest that the analysis of systemic BKV seroprevalence, as 21 
determined by IgG activity against viral capsid proteins, fails to support an association between 22 
BKV infection and PCa (38). Instead, humoral, and, most of all, cellular responsiveness to BKV 23 
 22 
L-Tag skewed towards an immune regulatory gene expression profile, and characterized by a 1 
high IL-10/IFN-γ gene expression ratio, appear to be associated with PCa. Most conspicuously, 2 
this pattern of responsiveness is typically detectable in cells from patients with recurrent PCa. 3 
Interestingly, recent data indicate that PBMC from patients with MCC might fail to produce 4 
IFN-γ in response to specific L-Tag peptides (28). In this case as well, infection by MCV was 5 
found to induce L-Tag specific humoral responses predominantly in cancer bearing patients. 6 
However, L-Tag stimulated IL-10 production was not explored.  7 
It is tempting to speculate that the skewed cytokine gene expression signature typically 8 
detectable upon L-Tag peptide stimulation could be due to immune regulatory activities of cells 9 
preferentially secreting IL-10. However, while IFN-γ is only produced by T and NK cells, IL-10 10 
can be produced by several cell types, including tumor cells (10, 21), virally infected cells (9), 11 
different types of activated antigen presenting cells and T cells.  12 
 We found similar numbers of circulating cells expressing classical CD4+CD25+(high)FoxP3+ 13 
Treg phenotype in patients with PCa or BPH, irrespective of their BR and L-Tag molecular 14 
status. However, our data indicate that in vitro stimulation of PBMC from patients with recurrent 15 
BKV+ PCa, but not from patients with BKV+ PCa and no BR evidence or from patients with 16 
BKV+ BPH, results in the significant expansion of cells characterized by a typical Treg 17 
phenotype. These lymphocytes uniformly express IL-10, as detectable by intracellular staining, 18 
consistent with a predominant role in the elicitation of the skewed cytokine gene expression 19 
profile induced by BKV L-Tag in PBMC from patients bearing BKV+ PCa. Admittedly, the sole 20 
expression and/or release of IL-10 does not represent a reliable signature for regulatory T cell 21 
involvement (44) since it can be also induced in effector cells to reduce inflammation at the site 22 
of acute viral infections (49). However, the detection of this cytokine in combination with both 23 
 23 
TGF-β1 and permanent FoxP3 expression is usually associated to regulatory functions (2, 52). 1 
Most importantly, L-Tag induced CD4+CD25+(high)FoxP3+CD103+ T cells also display a 2 
remarkable capacity to inhibit proliferation of autologous anti-CD3/CD28 stimulated CD4+CD25- 3 
lymphocytes as compared to HCMVpp65 stimulated CD4+CD25+(high)FoxP3+CD103+/- T cells, in 4 
accordance to recently published reports (46, 56). Collectively, these data hint to mechanisms 5 
potentially underlying our findings in ex vivo activated PBMC. 6 
Immune regulatory activities driven by viral antigens and promoting the establishment of 7 
chronic infections have already been described (18, 20). These functions can be elicited by 8 
recruiting either CD4+ or CD8+ Treg, depending on type of infections (30). The involvement of 9 
both Treg subsets is dictated by HLA-restricted virus-specific stimulation taking place at the site 10 
of infection and presupposes both the expression of viral antigens and of Treg-derived cytokines, 11 
such as IL-10 and TGF-β1 (18, 30, 31).  Moreover, circulating tumor associated antigen specific 12 
T cells with a regulatory phenotype (CD25+(high)FoxP3+) and the ability of secreting IL-10 and 13 
exerting suppressive functions have also been described in metastatic melanoma patients (51).  14 
Still unclear is the molecular background preferentially favoring the expansion of these cells 15 
in patients bearing BKV+ PCa. It is of relevance, however, that prostate tissues appear to be 16 
characterized by features consistent with an immunosuppressive microenvironment. Infiltrating 17 
CD4+ and CD8+ T lymphocytes (TIL) are predominantly characterized by regulatory (32, 36) and 18 
functionally exhausted (PD-1+, B7-H1+) phenotypes (8, 17, 47). Furthermore, enhanced 19 
suppressive function of adaptive CD4+ Treg has been observed in the peripheral blood of patients 20 
with PCa and found to correlate with metastatic behavior (55).  21 
We previously showed that indoleamine-2, 3-deoxygenase (IDO) gene is frequently 22 
expressed to high extents in PCa (19). The specific gene product plays a key role in tryptophan 23 
 24 
metabolism and its enhanced activities might result in both the depletion of an amino acid 1 
essential for lymphocyte metabolism and in the generation of toxic metabolites (53). In addition, 2 
arginase production by macrophages infiltrating prostatic tissues has been shown to favor the 3 
induction of anergy in resident lymphocytes (8). Therefore, in patients bearing a BKV+ PCa, 4 
presentation of L-Tag to T cells might occur in conditions likely favoring the generation of 5 
immune responses characterized by a high IL-10/IFN-γ gene expression ratio. 6 
Most obviously, our data do not allow the postulation of any causal relationship between 7 
features of L-Tag specific immune responses, BKV infection and cancer. Nevertheless, they 8 
suggest the existence of a complex interaction of potential clinical relevance. 9 
Our study has a major limitation. Indeed, although it capitalizes on the analysis of specific 10 
immune responses in a substantial number of patients, the number of informative cases, e.g. 11 
patients bearing BKV+ lesions with or without BR, is relatively modest. Therefore, additional 12 
investigations confirming these results in a larger number of cases are obviously warranted. 13 
 However, our data provide important novel contributions to the analysis of the increasingly 14 
puzzling relationship between BKV infection and PCa by identifying subpopulations of patients 15 
deserving major attention in translational research and, most importantly, by highlighting subtle 16 
peculiarities of immune responses against BKV L-Tag in patients with PCa, with previously 17 
unsuspected associations with the clinical course of this disease.    18 
19 
 25 
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Figure legends 1 
Figure 1. BKV L-Tag DNA detection in tissue specimens and L-Tag or VP1 specific IgG 2 
response. (A) BKV L-Tag DNA was detectable in either PCa (n=18/43, 42%) or BPH (n=12/38, 3 
32%) surgically excised lesions. Quantitative data, expressed as copy number/105 cells were 4 
comparatively analyzed in positive PCa and BPH tissues.  To emphasize the specificity of BKV 5 
detection in prostate specimens, JCV L-Tag sequence was also investigated. Rare samples 6 
displayed  JCV L-Tag sequences either in patients with PCa (n=1/40, 2%) or with BPH (n=1/36, 7 
3%) with copy numbers markedly below 50 copies/105 cells, the arbitrary limit for BKV L-Tag 8 
DNA detection selected in our study (cut-off; dotted line). (B) BKV L-Tag and VP1 IgG titer in 9 
patients with either PCa or BPH, stratified according to BKV L-Tag DNA molecular testing in 10 
their tissues (positive lesions: BKV+ or +; negative lesions: BKV- or -). Cut-off (dotted line) was 11 
set at 0.04, the lowest OD492 sufficient to detect antibody activity. Boxes and whiskers (CI 95%) 12 
are also reported.  13 
  14 
Figure 2. Cytokine gene expression upon ex vivo BKV L-Tag peptide-pool stimulation in 15 
PBMC from patients bearing PCa, BPH or healthy donors (HD).   16 
(A) IFN-γ (white boxes) and IL-10 (grey boxes) cytokine gene expression was measured upon ex 17 
vivo BKV L-Tag peptide pool stimulation of PBMC from patients with PCa and PBH, stratified 18 
according to their L-Tag specific IgG activity (IgG+ ≥0.04). HIV peptide-pool stimulation was 19 
used as background to compute fold changes in specific gene expression (cytokine gene relative 20 
quantification (2–ΔΔCt)). An arbitrary cut-off was set at 2-fold (dotted line). Boxes and whiskers 21 
(CI 95%) were reported to show the significance of differential gene expression for each cytokine 22 
based on patients’ group stratifications. (B) Correlation (Spearman ρ) between cytokine gene 23 
 32 
expression, as detected upon ex vivo L-Tag peptide-pool stimulation of PBMC from BKV L-Tag 1 
seropositive patients with PCa or BPH and L-Tag specific IgG. Ratios of IL-10/IFN-γ gene 2 
expression induced by L-Tag stimulation were plotted against L-Tag specific IgG activity for all 3 
IgG+ PCa (n=46; upper quadrant) and IgG+ BPH (n=38; lower quadrant) patients. Cut-off 4 
(dotted line) was set at 0.04 OD492 (see legend to figure 1). (C) Boxes and whiskers (CI 95%) for 5 
IFN-γ (white boxes) and IL-10 (grey boxes) cytokine gene expression, as observed in PBMC 6 
from L-Tag IgG+ patients with PCa (n=46), age-matched patients with BPH (n=38) and non age, 7 
gender-matched healthy donors (HD; n=8) following ex vivo stimulation with BKV L-Tag 8 
peptide pool, CMV/EBV/influenza virus peptide pool (CEF) or PHA. HIV peptide-pool 9 
stimulation was used as background to compute fold changes in specific gene expression 10 
(cytokine gene relative quantification (2–ΔΔCt)). An arbitrary cut-off was set at 2-fold (dotted line).  11 
 12 
Figure 3. Cytokine gene expression pattern upon ex vivo BKV L-Tag peptide-pool 13 
stimulation in L-Tag IgG+ patients bearing BKV+ PCa or BPH. (A) IFN-γ (white boxes) and 14 
IL-10 (grey boxes) cytokine gene expression was analyzed upon ex vivo BKV L-Tag peptide pool 15 
stimulation of PBMC from patients with PCa and PBH, stratified according to their BKV L-Tag 16 
DNA molecular testing (positive lesions: BKV+ or +; negative lesions: BKV- or -). HIV peptide-17 
pool stimulation was used as background to compute fold changes in specific gene expression 18 
(cytokine gene relative quantification (2–ΔΔCt)). An arbitrary cut-off was set at 2-fold (dotted line). 19 
Boxes and whiskers (CI 95%) were reported to show the significance of differences observed for 20 
each cytokine gene expression based on patients’ group stratifications. (B) IFN-γ (white circles) 21 
and IL-10 (white squares) gene expression were measured upon L-Tag peptide-pool stimulation 22 
(cut-off 2-fold; dotted line) of PBMC from BKV+/IgG+ patients with PCa (n=17) or BPH (n=6). 23 
 33 
(C) IL-10/IFN-γ gene expression ratio observed following L-Tag peptide stimulation of PBMC 1 
from BKV+/IgG+ patients bearing BKV+ PCa or BKV+ BPH. Boxes and whiskers (CI 95%) 2 
were reported to show differences of cytokine expression pattern between BKV+/IgG+ patients 3 
groups. 4 
  5 
Figure 4. L-Tag peptide-pool induced cytokine gene expression in L-Tag IgG+ patients 6 
bearing BKV+ PCa with or without evidence of biochemical recurrence (BR)  7 
(A) Ratios of IL-10/IFN-γ (grey boxes) and TGF-β1/IFN-γ (white boxes) gene expression, as 8 
detected following L-Tag peptide specific ex vivo stimulation of PBMC from L-Tag IgG+ 9 
patients bearing BKV+ PCa with (n=7) or without (n=8) BR evidence. HIV peptide-pool 10 
stimulation was used as background to compute gene expression fold changes (2–ΔΔCt; cut-off 2-11 
fold). Boxes and whiskers (CI 95%) were reported to show significant differences for both IL-12 
10/IFN-γ  and TGF-β1/IFN-γ  gene expression ratios according to BR patients’ stratifications. (B) 13 
IFN-γ (white bars), IL-10 (light grey bars) and TGF-β1 (dark grey bars) protein production from 14 
2-week in vitro expanded PBMC from L-Tag IgG+ patients bearing BKV+ PCa with (n=7) or 15 
without (n=8) BR. HIV peptide-pool in vitro stimulation was used as control. Histograms ± 16 
standard errors are reported.  17 
  18 
Figure 5. BKV L-Tag-specific expansion of CD4+ T cell with a CD25+(high)FoxP3+ regulatory 19 
phenotype in L-Tag IgG+ patients bearing BR+BKV+ PCa  20 
(A) Representative FACS density plot analysis of ex vivo FoxP3 expression in CD4+CD25+ T 21 
cells in PBMC from a PCa patient (upper panel) and a HD (lower panel). The histogram shows 22 
means ± standard errors of ex vivo detected frequencies of CD4+CD25+FoxP3+ T cells in L-Tag 23 
 34 
IgG+ patients with BR+/BKV+ PCa (dotted bar), BR-/BKV+ PCa (checkered bar) and BKV+ 1 
BPH (striped bar), as compared to HD (black bar). (B) Gating strategies for CD4+ T cell with a 2 
CD25+(high)FoxP3+ phenotype, as detectable upon peptide stimulation. (C) Percentages of 3 
CD4+CD25+(high)FoxP3+ T cells in PBMC from L-Tag IgG+ patients with BR+/BKV+ PCa (n=7), 4 
BR-/BKV+ PCa (n=8) or BKV+ BPH (n=7) upon HIV peptide-pool (circles) or L-Tag peptide-5 
pool (squares) stimulation. HCMVpp65340-355 promiscuous peptide (triangles). was also used as 6 
additional control on BR+/BKV+ PCa (n=6), BR-/BKV+ PCa (n=7) or BKV+ BPH (n=5) L-Tag 7 
IgG+ patients. (D) Mean Fluorescence Intensity (MFI) of FoxP3 intracellular staining of cultured 8 
cells from L-Tag IgG+ patients with BR+/BKV+ PCa, BR-/BKV+ PCa or BKV+ BPH, following 9 
HIV peptide-pool (circles), HCMVpp65340-355 promiscuous peptide (triangles) or L-Tag peptide-10 
pool (squares) in vitro stimulation. Overlaid histograms refer to FoxP3 MFI upon L-Tag peptide-11 
pool and HIV peptide-pool (above) or L-Tag peptide-pool and HCMVpp65340-355 promiscuous 12 
peptide (below) stimulations, as compared to isotype staining. 13 
 14 
Figure 6. Generation of BKV L-Tag specific functional CD4+CD25+(high)FoxP3+ T cells with 15 
effector-memory regulatory phenotype and suppressive activity.  16 
(A) Intracellular IL-10 protein production in CD4+CD25+(high)CD127-(dim) T cells from one 17 
representative L-Tag IgG+ patient bearing a BKV+ PCa with BR, out of three studied, following 18 
L-Tag peptide-pool stimulation (right quadrant), as compared to HCMVpp65340-355 promiscuous 19 
peptide stimulation (middle quadrant) and to negative control HIV peptide-pool stimulation (left 20 
quadrant). (B) Expression of the regulatory T cell activation marker CD103 in IL-10-secreting 21 
CD4+CD25+(high)CD127-(dim) T cells (see panel A) from one representative L-Tag IgG+ patient 22 
bearing a BKV+ PCa with BR, out of three tested. Overlaid histograms refer to L-Tag peptide-23 
 35 
pool stimulated cells (black line), HCMVpp65340-355 stimulated cells (dark gray line) or negative 1 
control HIV peptide-pool stimulated cells (light grey line). (C) Proliferation index of anti-2 
CD3/CD28 stimulated CD4+CD25- T cells from one representative L-Tag IgG+ patient bearing a 3 
BKV+ PCa with BR, out of three tested, co-cultured with autologous L-Tag peptide-pool 4 
(circles) or HCMVpp65340-355 induced IL-10-secreting CD4+CD25+(high)CD127-(dim) T cells 5 
(squares), or cultured alone (triangles) over 8 days. WST-1(OD450) values were plotted against 6 
days of incubation in co-cultures performed at a 0.5:1 ratio. (D) Mean±SE of proliferation index 7 
of anti-CD3/CD28 stimulated CD4+CD25- T cells from the three IgG+ patients with BR+/BKV+ 8 
PCa tested, co-cultured as described above.    9 
10 
 36 
 Table 1: Patients PSA, PCa Gleason score, L-Tag molecular testing and IgG serology 1 
 2 
 37 
Table 2: Analysis of L-Tag IgG+ patients bearing BKV+ PCa with or without BR 1 
 2 
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